SERB Pharmaceuticals Acquires Idefirix® European and MENA Rights from Hansa Biopharma for €115 Million
SERB Pharmaceuticals has agreed to pay €115 million for exclusive development and commercialization rights to Idefirix® (imlifidase) across Europe and the Middle East and North Africa, acquiring the asset from Hansa Biopharma AB (Nasdaq…
By Kwame Asante·Jun 23, 2026·2 min read·markets·MS
Source: globenewswire.com
© 2026 NewsMeter
MarketsAug 23, 2026
Equal-weight S&P 500's flagship trade crosses $100 billion as the strategy leads the 2026 market
1 min
Markets · MUAug 20, 2026
Micron CEO challenges memory bear case in Jim Cramer interview
1 min
Markets · GOOGLAug 15, 2026
$17 billion Alphabet buy lifts Google's parent to third-largest Berkshire holding
1 min